JP2001514858A - アンテナペディアのホメオドメインを含むコンジュゲート - Google Patents

アンテナペディアのホメオドメインを含むコンジュゲート

Info

Publication number
JP2001514858A
JP2001514858A JP2000508817A JP2000508817A JP2001514858A JP 2001514858 A JP2001514858 A JP 2001514858A JP 2000508817 A JP2000508817 A JP 2000508817A JP 2000508817 A JP2000508817 A JP 2000508817A JP 2001514858 A JP2001514858 A JP 2001514858A
Authority
JP
Japan
Prior art keywords
conjugate
region
substrate
protein
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000508817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001514858A5 (enExample
Inventor
クリサンチ，アンドレア
Original Assignee
インペリアル カレッジ イノベーションズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インペリアル カレッジ イノベーションズ リミテッド filed Critical インペリアル カレッジ イノベーションズ リミテッド
Publication of JP2001514858A publication Critical patent/JP2001514858A/ja
Publication of JP2001514858A5 publication Critical patent/JP2001514858A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Variable-Direction Aerials And Aerial Arrays (AREA)
  • Medicinal Preparation (AREA)
JP2000508817A 1997-09-02 1998-09-02 アンテナペディアのホメオドメインを含むコンジュゲート Pending JP2001514858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9718609.2A GB9718609D0 (en) 1997-09-02 1997-09-02 Fusion protein
GB9718609.2 1997-09-02
PCT/GB1998/002628 WO1999011809A1 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia

Publications (2)

Publication Number Publication Date
JP2001514858A true JP2001514858A (ja) 2001-09-18
JP2001514858A5 JP2001514858A5 (enExample) 2006-01-05

Family

ID=10818419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000508817A Pending JP2001514858A (ja) 1997-09-02 1998-09-02 アンテナペディアのホメオドメインを含むコンジュゲート

Country Status (10)

Country Link
US (2) US7968512B2 (enExample)
EP (1) EP1009847A1 (enExample)
JP (1) JP2001514858A (enExample)
AU (1) AU737829B2 (enExample)
BR (1) BR9811744A (enExample)
CA (1) CA2301157A1 (enExample)
GB (1) GB9718609D0 (enExample)
IL (2) IL134602A0 (enExample)
NZ (1) NZ503007A (enExample)
WO (1) WO1999011809A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540611A (ja) * 2007-10-05 2010-12-24 トロジャン テクノロジーズ リミテッド Ｎｏｔｃｈ経路阻害剤を用いて癌を治療する方法
JP2012523244A (ja) * 2009-04-14 2012-10-04 トロジャン テクノロジーズ リミテッド 治療用アンテナペディア−抗体分子およびその使用法
JP2016527199A (ja) * 2013-06-11 2016-09-08 ポルタゲ ファーマシューティカルス エルティーディー． 生物学的に活性な特異的カーゴペプチドと結合したヒト由来の細胞透過性ペプチドの構造、製造および使用

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273192A1 (en) * 1996-12-02 1998-06-11 Wake Forest University Inactivation of hiv co-receptors as therapy for hiv infection
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
ES2318906T3 (es) 1998-11-13 2009-05-01 Cyclacel Limited Vectores de transposicion derivados de helice 3 de homeodominio de antennapedia.
EP1140202A1 (en) 1998-12-24 2001-10-10 Ucb S.A. Peptidic product, process and composition
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
AU775001B2 (en) * 1999-03-31 2004-07-15 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
AU3368301A (en) * 2000-01-07 2001-07-16 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
EP1118668A1 (en) * 2000-01-07 2001-07-25 ARTEMIS Pharmaceuticals GmbH Transduction of recombinases for inducible gene targeting
GB0003284D0 (en) * 2000-02-15 2000-04-05 Secr Defence Brit Anti-viral therapy
IL151910A0 (en) * 2000-04-12 2003-04-10 Implyx Ltd Compositions for drug delivery
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
KR100374050B1 (ko) * 2000-07-26 2003-03-03 최수영 세포침투성 융합단백질, 이를 코딩하는 재조합폴리뉴클레오타이드 및 발현벡터
WO2002020737A2 (en) * 2000-09-07 2002-03-14 Vanderbilt University Genome engineering by cell-permeable dna site-specific recombinases
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
WO2002098365A2 (en) * 2001-06-07 2002-12-12 Skinmedica, Inc. Conditioned cell culture media and uses thereof
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
GB0124391D0 (en) * 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
DE102007041655A1 (de) 2007-09-03 2009-03-05 Medicyte Gmbh Vermehrung von primären Zellen und deren Verwendung
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
WO2012154684A2 (en) * 2011-05-06 2012-11-15 University Of Rochester Method of preventing development of psoriatic lesions
WO2012174028A2 (en) * 2011-06-13 2012-12-20 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
CA3233345A1 (en) 2012-04-09 2013-10-17 Case Western Reserve University Compositions and methods for inhibiting the activity of lar family phosphatases
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
EP2927685A1 (en) 2014-04-02 2015-10-07 Medicyte GmbH Suitable hepatocytes for in-vitro hepatitis tests
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
RU2708375C2 (ru) 2015-03-02 2019-12-06 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс Пептиды для ингибирования ангиогенеза
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CA3020344A1 (en) 2016-04-07 2017-10-12 Case Western Reserve University Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP3612191B1 (en) 2017-04-19 2026-03-11 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
AU2018301399B2 (en) 2017-07-11 2024-08-29 Case Western Reserve University Compositions and methods for treating myelin disorders
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6008026610, Ｊ． Ｃｅｌｌ Ｓｃｉ．， １９９２年， ｖｏｌ． １０２， ｐ． ７１７−７２２ *
JPN6008026613, Ｍｏｌ． Ｅｎｄｏｃｒｉｎｏｌ．， １９９４年， ｖｏｌ． ８， ｎｏ． ９， ｐ． １２７８−１２８７ *
JPN6009011813, Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ． ＵＳＡ， １９９１年， ｖｏｌ． ８８， ｐ． １８６４−１８６８ *
JPN7008004579, Ｃｕｒｒ． Ｏｐｉｎ． Ｎｅｕｒｏ．， １９９６年， ｖｏｌ． ６， ｐ． ６２９−６３４ *
JPN7008004580, Ｊ． Ｉｍｍｕｎｏｌ．， １９９６年， ｖｏｌ． １５７， ｐ． ６５０−６５５ *
JPN7008004581, Ｊ． Ｂｉｏｌ． Ｃｅｈｍ．， １９９６年， ｖｏｌ． ２７１， ｎｏ． ３０， ｐ． １８１８８−１８１９３ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540611A (ja) * 2007-10-05 2010-12-24 トロジャン テクノロジーズ リミテッド Ｎｏｔｃｈ経路阻害剤を用いて癌を治療する方法
JP2012523244A (ja) * 2009-04-14 2012-10-04 トロジャン テクノロジーズ リミテッド 治療用アンテナペディア−抗体分子およびその使用法
JP2016527199A (ja) * 2013-06-11 2016-09-08 ポルタゲ ファーマシューティカルス エルティーディー． 生物学的に活性な特異的カーゴペプチドと結合したヒト由来の細胞透過性ペプチドの構造、製造および使用
US10301629B2 (en) 2013-06-11 2019-05-28 Portage Pharmaceuticals Ltd. Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
JP2019116477A (ja) * 2013-06-11 2019-07-18 ポルタゲ ファーマシューティカルス エルティーディー． 生物学的に活性な特異的カーゴペプチドと結合したヒト由来の細胞透過性ペプチドの構造、製造および使用
US10947539B2 (en) 2013-06-11 2021-03-16 Portage Pharmaceuticals Ltd. Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
JP2021193112A (ja) * 2013-06-11 2021-12-23 ピーピーエル（ビーブイアイ）リミテッド 生物学的に活性な特異的カーゴペプチドと結合したヒト由来の細胞透過性ペプチドの構造、製造および使用

Also Published As

Publication number Publication date
NZ503007A (en) 2000-11-24
IL134602A0 (en) 2001-04-30
US20080317773A1 (en) 2008-12-25
US7968512B2 (en) 2011-06-28
US8735340B2 (en) 2014-05-27
AU737829B2 (en) 2001-08-30
BR9811744A (pt) 2002-01-02
GB9718609D0 (en) 1997-11-05
IL134602A (en) 2006-10-31
CA2301157A1 (en) 1999-03-11
US20110256168A1 (en) 2011-10-20
WO1999011809A1 (en) 1999-03-11
AU8877698A (en) 1999-03-22
EP1009847A1 (en) 2000-06-21

Similar Documents

Publication Publication Date Title
US7968512B2 (en) Conjugates that contain the homeodomain of antennapedia
JP6942744B2 (ja) 生物学的に活性な特異的カーゴペプチドと結合したヒト由来の細胞透過性ペプチドの構造、製造および使用
TW565570B (en) Human IL-13 receptor beta
JP2003534821A (ja) Ｔ細胞レセプター融合体および結合体ならびにそれらの使用方法
JPH02501113A (ja) リンパ球機能関連抗原―３（ｌｆａ―３）を製造するためのｄｎａ配列、組換ｄｎａ分子及び方法
JPH09511916A (ja) 核酸伝達系
WO2021228052A1 (zh) 生物大分子靶向特异性补体抑制剂及其制备方法与应用
JP2026505430A (ja) トランスポザーゼ、トランスポゾン、トランスポゾンシステムおよびそれらの応用
JP2007527695A (ja) グリコシルホスファチジルイノシトールを含有するポリペプチド
AU710551B2 (en) Nucleic acid encoding a nervous tissue sodium channel
JP3340128B2 (ja) ヒト神経細胞接着因子ｌ１及びその製造方法並びにそれをコードする遺伝子
JPH10500311A (ja) 核タンパク質と相互作用する因子
CN106701764B (zh) 15kDa硒蛋白基因的启动子及其核心区与应用
JPH05508995A (ja) 異種蛋白産生読ストレプトミセス・ベクター
WO2001040463A1 (fr) Nouvelle proteine endoplasmique a reticulum localise, remedes contenant cette proteine destines a des maladies associees a une anomalie glycoproteique, adn codant cette proteine et remedes genetiques contenant cet adn destines au traitement de maladies associees a une anomalie glycoproteique
JPS62151182A (ja) 遺伝子及びその製造方法
JPH06503003A (ja) ストレプトリシンｏ誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080901

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090714

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090812

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100413